NanoString Technologies use PAM50 gene to look for breast cancer
Jun 3, 2011
At the 2011 American Society of Clinical Oncology meeting in Chicago, Illinois, the life sciences company NanoString Technologies, Inc. will present resesarch concerning the PAM50 gene signature and breast cancer profiling.
The meeting will be held between June 3 and 7, and feature at least five talks related to the PAM50 gene.
"We are encouraged to see the substantial body of evidence on the potential clinical utility of intrinsic subtyping breast cancer via the PAM50 gene signature continues to grow. We look forward to collaborating with leading breast cancer researchers to further demonstrate the clinical utility of the PAM50 signature," said Brad Gray, President and CEO of NanoString Technologies.
A gene signature is a group of several genes which together may contribute to a characteristic, in this case breast cancer.
Breast cancer affects more women in the U.S. than any other cancer besides skin cancer, according to the American Cancer Society. One out of every eight women in the U.S. will be diagnosed with breast cancer at some point in her lifetime. Men are also susceptible to the illness, although at a much smaller risk level.